Non‑Alcoholic Fatty Liver Disease (NAFLD)

Overview

Non‑alcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions characterized by the accumulation of excess fat (≥5% of hepatocytes) in the liver of people who drink little or no alcohol. It ranges from simple steatosis (fatty liver) to non‑alcoholic steatohepatitis (NASH), which involves inflammation and can progress to fibrosis, cirrhosis, and liver cancer.

NAFLD is now the most common chronic liver disease worldwide, affecting roughly 25% of adults in the United States and an even higher proportion in individuals with obesity or type 2 diabetes [1][2].

Symptoms Checklist

Most people with early NAFLD are asymptomatic. When symptoms appear, they are often vague. Use the checklist below to discuss any concerns with your health‑care provider.

• ☐ Unexplained fatigue or low energy
• ☐ Right‑upper‑quadrant discomfort or mild abdominal pain
• ☐ Unintended weight loss
• ☐ Generalized itching (pruritus)
• ☐ Enlarged liver (detected on exam or imaging)
• ☐ Dark urine or pale stools (possible sign of advanced disease)
• ☐ Swelling in the abdomen or legs (ascites or edema – usually in later stages)

Risk Factors

NAFLD is closely linked to metabolic health. The following groups have a higher risk:

• Obesity – especially central (abdominal) obesity (BMI ≥ 30 kg/m²).
• Type 2 diabetes mellitus or pre‑diabetes.
• Insulin resistance – often seen in metabolic syndrome.
• Hyperlipidemia – high triglycerides, low HDL, or elevated LDL.
• Hypertension.
• Polycystic ovary syndrome (PCOS).
• Sleep apnea (associated with obesity).
• Age > 40 years (risk rises with age).
• Genetic predisposition – e.g., variants in PNPLA3 gene.
• Certain medications (e.g., corticosteroids, amiodarone, tamoxifen) that promote fat deposition.

Diagnosis

Diagnosing NAFLD involves a combination of clinical assessment, blood tests, imaging, and sometimes liver biopsy.

Step‑by‑step approach

1. Medical history & physical exam – excluded significant alcohol intake (< 30 g/day for men, < 20 g/day for women) and identified risk factors.
2. Laboratory tests
   • Elevated liver enzymes (ALT, AST) – usually mild‑to‑moderate.
   • Fasting lipid panel, glucose, HbA1c.
   • Exclusion labs: viral hepatitis serology, autoimmune markers, iron studies.
3. Imaging
   • Abdominal ultrasound – first‑line, detects hepatic steatosis with ≈ 80% sensitivity.
   • Transient elastography (FibroScan) – measures liver stiffness (fibrosis) and controlled attenuation parameter (fat).
   • CT or MRI (especially MRI‑PDFF) – more accurate but costly; used when ultrasound is equivocal.
4. Liver biopsy – gold standard for distinguishing simple steatosis from NASH and grading fibrosis. Recommended when non‑invasive tests suggest advanced disease or when other causes need exclusion.

Treatment Options

There is no specific medication approved solely for NAFLD, but several strategies aim to halt or reverse disease progression.

Medical Therapies

• Weight‑loss pharmacotherapy (e.g., GLP‑1 receptor agonists like semaglutide) – shown to reduce liver fat and improve NASH histology in trials [3].
• Insulin‑sensitizers – pioglitazone can improve NASH in non‑diabetic patients, but long‑term safety must be weighed.
• Vitamin E (800 IU/day) – may benefit selected non‑diabetic NASH patients, per AASLD guidelines [4].
• Lipid‑lowering agents – statins are safe in NAFLD and treat dyslipidemia; they do not directly treat liver fat but reduce cardiovascular risk.
• Clinical trials – many agents (e.g., obeticholic acid, firsocostat) are under investigation.

Lifestyle & Home‑based Interventions

• Weight loss – 7–10 % reduction in body weight improves steatosis; ≥ 10 % may improve NASH and fibrosis.
• Dietary pattern – Mediterranean diet, low‑simple‑carbohydrate, high‑fiber, and reduced saturated‑fat intake.
• Physical activity – ≥ 150 min/week of moderate‑intensity aerobic exercise plus resistance training twice weekly.
• Limit fructose & sugary beverages – high fructose corn syrup is linked to hepatic fat accumulation.
• Avoid hepatotoxic substances – unnecessary over‑the‑counter meds, supplements, and alcohol.

Prevention

Because NAFLD is tightly linked to metabolic health, primary prevention focuses on maintaining a healthy weight and metabolic profile.

• Adopt a balanced diet rich in vegetables, whole grains, lean protein, and healthy fats (olive oil, nuts).
• Engage in regular physical activity (at least 30 minutes most days).
• Maintain glycemic control if you have diabetes or pre‑diabetes.
• Control blood pressure and lipid levels with lifestyle and, when needed, medication.
• Screen high‑risk individuals (obesity, type 2 diabetes) with liver enzymes or ultrasound every 1–2 years.

Living With Non‑Alcoholic Fatty Liver Disease (NAFLD)

Adapting day‑to‑day habits can help keep the disease stable and lower the risk of progression.

• Track your weight – aim for gradual loss (0.5–1 kg per week).
• Meal planning – cook at home, keep a food diary, and use portion control.
• Stay hydrated – water supports liver metabolism; limit sugary drinks.
• Regular follow‑up – schedule liver‑function tests and imaging per your physician’s recommendation.
• Mind‑body health – stress can worsen insulin resistance; consider yoga, meditation, or counseling.
• Avoid unnecessary supplements – many “liver detox” products have no proven benefit and may be harmful.
• Vaccinations – stay up to date on hepatitis A and B vaccines.

When to Seek Emergency Care

While NAFLD usually progresses slowly, certain complications require urgent medical attention:

• Sudden, severe abdominal pain (possible hepatic rupture or acute pancreatitis).
• Yellowing of the skin or eyes (jaundice) accompanied by confusion or drowsiness – signs of liver failure.
• Rapid swelling of the abdomen (ascites) with shortness of breath.
• Unexplained bleeding or easy bruising (coagulopathy).
• Fever, chills, or severe vomiting in a patient with known cirrhosis – risk of infection (spontaneous bacterial peritonitis).

If any of these occur, call emergency services (911 in the U.S.) or go to the nearest emergency department.

Medical Disclaimer: This guide provides general information and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified health‑care provider for personalized guidance regarding your health condition.

Sources:
[1] Mayo Clinic. “Non‑alcoholic fatty liver disease (NAFLD).” https://www.mayoclinic.org
[2] Centers for Disease Control and Prevention (CDC). “Non‑alcoholic fatty liver disease.” https://www.cdc.gov
[3] NIH – National Institute of Diabetes and Digestive and Kidney Diseases. “Semaglutide for NASH.” https://www.niddk.nih.gov
[4] American Association for the Study of Liver Diseases (AASLD) Guidelines. “Management of NAFLD.” https://www.aasld.org